

Guidance for patients on SGLT2 inhibitors

The following statement has been approved by the Diabetes & Endocrinology Working group in Dorset to enable primary care prescribers to appropriately manage patients with diabetes taking sodium-glucose co-transporter 2 (SGLT2) inhibitors:

The D&E working group in Dorset is aware of the Hampshire guidance around SGLT2 inhibitors that has been circulated locally. There was recently a Drug Safety Update issued about the SGLT2 inhibitors and ketone monitoring <https://www.gov.uk/drug-safety-update/sglt2-inhibitors-monitor-ketones-in-blood-during-treatment-interruption-for-surgical-procedures-or-acute-serious-medical-illness>

At this time patients with type 1 diabetes taking SGLT2i should stop taking these. These patients should all be secondary care. For patients with type 2 diabetes treatment should continue as advised and patients should follow their usual sick day rules, unless further national guidance is published. A copy of the sick days rules guidance can be found https://abcd.care/sites/abcd.care/files/site_uploads/Resources/Position-Papers/SGLT2-inhibitors-ABCD.pdf

SGLT2 inhibitors include ertugliflozin, canagliflozin, dapagliflozin and empagliflozin.

All practices should sign up to receive Drug Safety Updates as these are issued via the MHRA and not via the CAS alerting system.

April 2020

www.dorsetformulary.nhs.uk